Prevention Of Diabetes


Rating : Rate It:
 
Embed :   
Post a comment
    Post Comment on Twitter
Comments:  
1 Favorites
sbose64,INDIAN RAILWAYS   favourited this   4 Years ago.
First Prev [1] Next Last



  Notes
 
 
Slide 1 : Prevention Of Diabetes Dr. Wisam Ghadban, MD Consultant Physician Alkhor hospital HMC
Slide 2 : Prevention Of Diabetes Type 2 Diabetes: Hyperglycemia Insulin Resistance Relative Impairment of Insulin Secretion Pathogenesis: Poorly Understood Genetic Factors Affecting Insulin Release and Responsiveness + Environmental Factors Such As Obesity Are Important.
Slide 3 : Why Prevention Type 2 diabetes One of the most common chronic diseases in the US and one of the fastest growing diseases in the world. In US, lifetime risk of developing Diabetes for individuals born in the year 2000 is 33% for males 39% for females. Diabetes has enormous human and financial costs A leading cause of heart disease, blindness, kidney failure, and amputations Can be hard to treat once it develops There are ways to improve glucose tolerance
Slide 4 : Prediction Ability to predict and prevent type 2 diabetes in the general population is limited. However, we can identify hi risk groups of people such as: Close relatives with diabetes. Obesity and body fat distribution. Age and certain ethnic groups. Physical inactivity. Previous gestational diabetes. Elevated fasting glucose. Impaired glucose tolerance.
Slide 5 : Family History and Risk of NIDDM In the U.S. Positive family history imparts 2.7 fold risk of NIDDM after adjustment of other factors (Cowie, 1993). Based on NHANES II , risk of NIDDM among Caucasians was 1.8 fold higher with one family member, 3.8 fold higher with two or more family members compared to persons with no known family history of NIDDM.
Slide 6 : Obesity
Slide 7 : Fat distribution
Slide 8 : Birth Weight There is an apparent inverse relationship between birth weight and risk of type 2 diabetes. Subjects who had low birth weights have reduced beta cell function as adults, insulin resistance, and an increased incidence of type 2 diabetes.
Slide 9 : Impaired Glucose Tolerance? Risk factor for type 2 diabetes Increases risk of type 2 diabetes 5 - 8 fold 1- 9% per year develop type 2 diabetes Major risk factor for heart disease IGT may be the best time to intervene No symptoms May be reversible Diabetes complications have not developed
Slide 10 : Gestational Diabetes The risk of type 2 diabetes is higher in women who have gestational diabetes. They have defects in both insulin secretion and insulin action. 2 studies have shown a five year incidence of 47-50 percent for type 2 diabetes in women with gestational diabetes. The greatest increase in the risk was in the first five years.
Slide 11 : Diabetes Prevention Program Clinics . . . . . . . . . . . . . . . . . . . . . . . . . . 27 clinics 3,819 participants
Slide 12 : DPP Timeline Planning Phase Began Recruitment Began Troglitazone stopped Recruitment ended DMB Recommends Early Termination Volunteers unmasked
Slide 13 : DPP Goals Primary To prevent or delay type 2 diabetes in people with impaired glucose tolerance (IGT) Secondary Reduce heart disease and stroke Reduce risk factors for heart disease and stroke
Slide 14 : Who was eligible for the DPP? Individuals with IGT Fasting glucose 95-125 mg/dl American Indians ?125 mg/dl And 2 hour glucose 140-199 mg/dl Body mass index > 24 kg/m2 (Asians > 22 kg/m2 ) Age > 25 years Men and women All ethnic groups
Slide 15 : Study Interventions Screen Randomize Standard lifestyle teaching Intensive Lifestyle (n = 1079) Metformin (n = 1073) Placebo (n = 1082) Troglitazone n= 585 Until 6/98
Slide 16 : Lifestyle Intervention Intensive lifestyle goals Reduction of fat and calorie intake Physical activity at least 150 minutes/week Achieve and maintain at least 7% weight loss
Slide 17 : Metformin - 850 mg tablet once a day increasing after 4 weeks to two a day Troglitazone - 400 mg per day Placebo- Placebo tablets Interventions Medications
Slide 18 : Average Weight Change 0 6 12 18 24 30 36 42 Months in study Lifestyle Metformin + Placebo
Slide 19 : 0 1 2 3 4 0 10 20 30 40 Placebo (n=1082) Metformin (n=1073, p<0.001 vs. Plac) Lifestyle (n=1079, p<0.001 vs. Met , p<0.001 vs. Plac ) Percent of all participants developing diabetes Years in study Cumulative incidence (%) Lifestyle Metformin Placebo
Slide 20 : Development of Diabetes Placebo Life-style Metformin Percent developing 11.0% 4.8% 7.8% diabetes each year Reduction of diabetes ---- 58% 31% compared with placebo Placebo, Lifestyle and Metformin
Slide 21 : Percent of participants with normal glucose tolerance or diabetes at 3 years
Slide 22 : Diabetes incidence rates by BMI
Slide 23 : Conclusions Intensive Lifestyle and Metformin were accepted, well tolerated, and safe Intensive lifestyle achieved weight loss and increased activity
Slide 24 : Conclusions Intensive lifestyle intervention reduced the development of diabetes by 58% Metformin reduced the development of diabetes by 31% Troglitazone reduced the development of diabetes by 23% (used for only 10 months)
Slide 25 : Conclusions Intensive Lifestyle was more effective than metformin Intensive Lifestyle and Metformin were effective in both women and men and all ethnic-racial groups
Slide 26 : Conclusions Diabetes can be delayed or prevented for at least 3 years in people at high risk, such as those in the DPP

 


Related 

 
Free Powerpoint Templates
Add as Friend shouser     3 Years ago.
3984 Views, 1 favourite
children diabetes,diabetes causes,diabetes complications,diabetes control,diabetes cure,diabetes di    more
More By User

Flag as inappropriate





Browse | Powerpoint Templates | Tags | Contact | About Us | Privacy | FAQ | Blog

© Slideworld